Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Overview

About this study

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key inclusion criteria:

  1. Men and women, aged ≥18 and ≤ 75 years with a diagnosis of GPA or MPA according to the American College of Rheumatology/ European League Against Rheumatism 2022 (ACR/EULAR 2022) classification criteria
  2. Positive test for ANCA-autoantibodies
  3. GPA and MPA participants with severe active disease

Key exclusion criteria:

  1. Any condition that could prevent a complete washout of medications or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study
  2. Hypersensitivity and/or contraindications to any product to be given to the participant as part of the study protocol
  3. Other systemic autoimmune diseases requiring therapy
  4. Any medical conditions that are not related to GPA/MPA that would jeopardize the ability of the participant to tolerate CD19 CAR-T cell therapy
  5. Inadequate organ function

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 04/02/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ulrich Specks, M.D.

Contact us for the latest status

Contact information:

Josephine Baum

(507) 422-9010

Baum.Josephine@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Vikas Majithia, M.B.B.S., M.P.H.

Contact us for the latest status

Contact information:

Vikas Majithia M.B.B.S., M.P.H.

(904) 953-2062

Majithia.Vikas@mayo.edu

More information

Publications

Publications are currently not available